Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q6Q759

UPID:
SPG17_HUMAN

ALTERNATIVE NAMES:
Projection protein PF6 homolog

ALTERNATIVE UPACC:
Q6Q759; Q8NAZ1; Q9NT21

BACKGROUND:
The protein Sperm-associated antigen 17, with its alternative name Projection protein PF6 homolog, plays a crucial role in the function and structure of motile cilia, essential for normal spermatogenesis and male fertility. It is vital for the development of sperm flagellum and the assembly of the respiratory motile cilia central pair apparatus, excluding the brain ependymal cilia.

THERAPEUTIC SIGNIFICANCE:
Linked to Spermatogenic failure 55, a disorder marked by severely reduced sperm motility leading to male infertility, Sperm-associated antigen 17's function is critical. Exploring the functions of this protein opens avenues for potential therapeutic interventions in male infertility.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.